Please add the following paragraph and Table 8 to p. 43 at line 13.

## **Experimental Reagents**

Table 8 lists the  $A_{2A}$  adenosine agonists and antagonists that were used in Examples 14-18.

Table 8. Biologically Active A<sub>2a</sub> Adenosine Receptor Agonists and Antagonists.

	Compound	<u>Abbreviation</u>	<u>Activity</u>
	5'-N-ethylcarboxamidoadenosine	NECA	A <sub>2A</sub> agonist
)	N-[(1R)-1-methyl-1\2-phenylethyl]adenosine	R-PIA	A <sub>2A</sub> agonist
	8-cyclopentyl-1,3-dimethylxanthinge	CPX	A <sub>2b</sub> antagonist
	4-[2-[[6-Amino-9-(ethyl-B-D ribofuranuron-amindosyl)-9H-purin-2-yl]aminoethyl]benz-enepropanoic acid	CGS21680	A <sub>2A</sub> adenosine receptor agonist
	N-ethyl-1'-deoxy-1'-(6-amino-2-hexynyl-9H-purin9-yl)-beta-D-ribofura nuronamide	HENECA	A <sub>2a</sub> adenosine receptor agonist
	2-alkynyladenosine	YT-0146	A <sub>2a</sub> adenosine receptor agonist
	2-cyclohexylmethylidenehydrazinoadenosine	WRC0470	receptor agonist
	4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a] [1,3,5]triazin-5-ylamino]ethyl)phenol	ZM241385	A <sub>2A</sub> adenosine receptor antagonist
, ,			

## **IN THE ABSTRACT:**

Please add the following Abstract:

A3

N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as  $A_{2A}$ -adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for the therapeutic purposes and as adjuncts in cardiological imaging.

